Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.
The site in California has a successful regulatory track record and includes single-use bioreactors and associated downstream capabilities, Lonza said. The site employs more than 100 staff who will have the chance to keep working for Lonza, it added.
By Michael Shields
Source: Reuters
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
